Drug intelligence / Profile preview

CMG06

Development stage: Preclinical
Lead developer: Chengdu Chimagen Biosciences
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

CMG06 is a trispecific antibody currently in preclinical development by Chengdu Chimagen Biosciences for the treatment of solid tumors. As a multi-specific therapeutic, it is engineered to engage three distinct targets simultaneously, a strategy designed to enhance anti-tumor activity and potentially overcome resistance mechanisms associated with conventional monoclonal or bispecific antibodies. While the specific molecular targets for CMG06 have not been publicly disclosed by the developer, the candidate is part of a pipeline focused on leveraging novel immune-stimulating mechanisms for oncology.

Beyond the preview

Go deeper on CMG06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CMG06.

Explore the full profile